Page last updated: 2024-12-06

n-carbobenzoxyglycylproline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

N-carbobenzoxyglycylproline: RN given refers to (L)-isomer; inhibits prolyl oligopeptidase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID439540
CHEBI ID10096
SCHEMBL ID2228388
MeSH IDM0135792

Synonyms (30)

Synonym
n-[(benzyloxy)carbonyl]glycyl-l-proline
p0h ,
n-carbobenzoxyglycylproline
z-gly-pro-oh
C01632
1160-54-9
z-gly-pro
z-gly-pro, >=99.0% (tlc)
(2s)-1-[2-(phenylmethoxycarbonylamino)acetyl]pyrrolidine-2-carboxylic acid
A803553
(2s)-1-(2-{[(benzyloxy)carbonyl]amino}acetyl)pyrrolidine-2-carboxylic acid
n-cbz-glycyl-l-proline
AKOS015919518
ST51016177 ,
z-glycyl-l-proline
CHEBI:10096
SCHEMBL2228388
(s)-1-(2-(((benzyloxy)carbonyl)amino)acetyl)pyrrolidine-2-carboxylic acid
Q-101548
(2s)-1-[2-(benzyloxycarbonylamino)acetyl]pyrrolidine-2-carboxylic acid
mfcd00037341
l-proline, n-[(phenylmethoxy)carbonyl]glycyl-
(s)-1-(2-(benzyloxycarbonylamino)acetyl)pyrrolidine-2-carboxylic acid
l-proline,n-[(phenylmethoxy)carbonyl]glycyl-
DS-15003
Q27108580
AMY41412
DTXSID501292362
CS-0147302
z-l-glycyl-l-proline
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
peptideAmide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. X = OH, OR, NH2, NHR, etc.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (33.33)18.7374
1990's2 (33.33)18.2507
2000's2 (33.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]